If you've been following wellness forums this week, you've seen the headlines. "Peptides coming back." "BPC-157 legal again soon." "FDA approves peptides." Most of them are wrong — or at minimum, premature. Here's what is actually happening, and why the distinction matters.

What Is the PCAC — and Why Does It Have a Say on Peptides?

The Pharmacy Compounding Advisory Committee, or PCAC, is an independent advisory body that advises the FDA on which bulk drug substances may be used in compounded preparations under Section 503A of the Federal Food, Drug, and Cosmetic Act.

When a compound isn't commercially available as an FDA-approved drug, compounding pharmacies can sometimes prepare it — but only if it meets specific criteria. The PCAC evaluates whether a substance meets those criteria and gives the FDA a non-binding recommendation.

Non-binding is the operative word. The FDA can accept or reject PCAC recommendations. And even when it accepts them, the path to a final rule takes time.

What Is Actually Happening July 23-24?

The FDA has scheduled a PCAC public meeting for July 23-24, 2026. Per the published PCAC agenda (docket FDA-2025-N-6895), the committee will review the following bulk drug substances for potential inclusion on the 503A bulks list:

This is a review hearing — not an approval decision. The PCAC will hear scientific evidence, discuss each substance's safety and clinical profile, and vote on whether to recommend each for inclusion on the 503A list. That recommendation then goes to the FDA for rulemaking.

You can find the full hearing notice and agenda on the FDA's official PCAC meeting page.

The Public Comment Window — and Why July 9 Matters

Before the hearing, the FDA opens a public comment docket so patients, researchers, clinicians, and members of the public can submit written input. The docket for this hearing is FDA-2025-N-6895.

Here is the timeline you need to know:

Submit your comment through the FDA-2025-N-6895 docket on regulations.gov. Instructions are also on the FDA's PCAC landing page.

This is not a vote. Submitting a comment does not change FDA policy. But the public record shapes how the PCAC frames its deliberations, and an organized, evidence-grounded comment record has historically influenced committee recommendations. If you have a perspective on any of these compounds — clinical experience, research citations, patient history — today is the effective deadline.

This is the part of the story that most coverage is getting wrong.

Even a unanimous positive PCAC vote on July 24 does not immediately change anything. Here is the actual regulatory sequence:

  1. PCAC votes — recommends a substance for the 503A bulks list (or doesn't)
  2. FDA reviews the recommendation — there is no required timeline for this step
  3. FDA publishes a proposed rule — opens another public comment period (typically 60-90 days)
  4. FDA reviews comments and publishes a final rule — this alone typically takes 6-12 months at minimum from proposed rule to final, often longer
  5. Final rule takes effect — compounding pharmacies can now legally compound the substance at scale under Section 503A

From a positive PCAC vote to a final rule, the minimum realistic timeline is 6-12 months — and more commonly it runs longer. There is no version of the July 23-24 hearing where peptides become broadly available the following week.

What the hearing does do: it creates the administrative record that makes the rulemaking pathway possible. That is significant — but it is a beginning, not an end.

What This Means If You Are Currently Using or Interested in Peptide Protocols

The regulatory landscape for compounded peptides is actively evolving. That means a few things for people who take a supervised wellness approach:

Stay informed, not reactive. The PCAC process is slow by design. Social media headlines will outrun the actual timeline. Follow the FDA's official PCAC page for updates.

Work within supervised frameworks. Regardless of where the regulatory process lands, access to any compounded substance requires a licensed provider relationship. That framework exists for good reasons and does not change based on PCAC outcomes.

Ask questions. If you are currently working with a provider on a peptide protocol, ask them how the PCAC process affects your specific protocol. Your provider is the right source — not a forum post or a news headline.

Nuvari connects patients with licensed providers who supervise evidence-informed wellness protocols. If you have questions about supervised care options, you can explore our protocols or reach out directly.

A Note on the Broader Regulatory Context

The FDA has been actively reviewing the 503A bulks list for several years. Compounding oversight accelerated following a 2012 meningitis outbreak linked to a compounding pharmacy — the Drug Quality and Security Act (DQSA) passed that year created the 503A/503B framework that governs compounding today.

Bulk drug substances that are not on an approved list, not actively evaluated, or not FDA-approved are in a legal gray zone for compounding pharmacies. The PCAC hearing is the formal mechanism to move substances out of that gray zone — in either direction.

The July 23-24 hearing is part of a broader, multi-year FDA effort to clarify which compounds can move through the 503A pathway. Other substances have gone through this process before. Some were added to the list; some were not. The outcome is not predetermined.

FAQ Section

What is the PCAC and what does it do?

The Pharmacy Compounding Advisory Committee (PCAC) is an independent advisory body that advises the FDA on which bulk drug substances may be used in compounded preparations under Section 503A of the Federal Food, Drug, and Cosmetic Act. The PCAC reviews scientific evidence and votes on whether to recommend substances for the 503A bulks list. Recommendations are non-binding — the FDA makes the final rulemaking decision.

What peptides is the FDA reviewing at the July 2026 PCAC hearing?

Per the published PCAC agenda (docket FDA-2025-N-6895), the July 23-24, 2026 hearing covers seven bulk drug substances: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and Emideltide. The committee will evaluate each for potential inclusion on the 503A compounding bulks list.

Does a positive PCAC vote mean peptides become legal to compound immediately?

No. A positive PCAC vote is a recommendation, not a rule. After a vote, the FDA must review the recommendation, publish a proposed rule, accept public comments, and then publish a final rule — a process that typically takes 6-12 months at minimum, often longer. Nothing changes on the day of the hearing.

How do I submit a public comment on the PCAC hearing?

Submit your comment through the FDA-2025-N-6895 docket on regulations.gov by July 9, 2026 to ensure it reaches the Committee before the hearing. The docket remains open through July 22, 2026 — comments submitted after July 9 are still accepted and considered by the FDA, but will not be included in the Committee's pre-meeting record.

Should I change my wellness protocol based on the PCAC outcome?

That is a question for your provider. Any decision about a wellness protocol should be made in consultation with a licensed healthcare provider who understands your individual health history. The PCAC process is a regulatory and administrative event — protocol decisions should be made on clinical grounds with your provider's guidance.